Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy

Fangjuan Li, Hui Liu, Hongyu Wu, Shixiong Liang, Yaping Xu, Fangjuan Li, Hui Liu, Hongyu Wu, Shixiong Liang, Yaping Xu

Abstract

Background: Previous studies have found that patients with subclinical interstitial lung disease (ILD) are highly susceptible to developing radiation pneumonitis (RP) after thoracic radiation therapy. In the present study we aimed to evaluate the incidence of and risk factors for RP after thoracic intensity-modulated radiation therapy in lung cancer patients with subclinical ILD.

Methods: We retrospectively analyzed data from lung cancer patients with subclinical ILD who were treated with thoracic intensity-modulated radiation therapy with a prescribed dose of ≥ 50 Gy in our institution between January 2016 and December 2017.

Results: Eighty-seven consecutive lung cancer patients with subclinical ILD were selected for the study. The median follow-up period was 14.0 months. The cumulative incidence of grades ≥ 2 and ≥ 3 RP at one year was 51.0% and 20.9%, respectively. In the multivariate analysis, a mean lung dose ≥ 12 Gy was a significant risk factor for grade ≥ 2 RP (p = 0.049). Chemotherapy with gemcitabine in the past, V5 ≥ 50%, and subclinical ILD involving ≥ 25% of the lung volume were significantly associated with grade ≥ 3 RP (p = 0.046, p = 0.040, and p = 0.024, respectively).

Conclusion: Mean lung dose is a significant risk factor for grade ≥ 2 RP. Lung cancer patients who have received chemotherapy with gemcitabine in the past, V5 ≥ 50%, and those with subclinical ILD involving ≥ 25% of lung volume have an increased risk of grade ≥ 3 RP in lung cancer patients with subclinical ILD.

Keywords: ILD; Lung cancer; RP.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
a Cumulative incidence of grade ≥ 2 RP in patients with different involvement volumes of subclinical ILD; b Cumulative incidence of grade ≥ 3 RP in patients with different involvement volumes of subclinical ILD; c Cumulative incidence of grade ≥ 2 RP in patients who had (solid line) or had not (dashed line) received chemotherapy with gemcitabine in the past; d Cumulative incidence of grade ≥ 3 RP in patients who had (solid line) or had not (dashed line) received chemotherapy with gemcitabine in the past
Fig. 2
Fig. 2
Survival curve for all patients

References

    1. Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;85(2):444–450. doi: 10.1016/j.ijrobp.2012.04.043.
    1. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S70–76. doi: 10.1016/j.ijrobp.2009.06.091.
    1. Arrieta O, Gallardo-Rincón D, Villarreal-Garza C, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol. 2009;4(7):845–852. doi: 10.1097/JTO.0b013e3181a97e17.
    1. Meadors M, Floyd J, Perry MC. Pulmonary toxicity of chemotherapy. Semin Oncol. 2006;33(1):98–105. doi: 10.1053/j.seminoncol.2005.11.005.
    1. Zhang XJ, Sun JG, Sun J, et al. Prediction of radiation pneumonitis in lung cancer patients: a systematic review. J Cancer Res Clin Oncol. 2012;138(12):2103–2016. doi: 10.1007/s00432-012-1284-1.
    1. Dang J, Li G, Zang S, et al. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy. Radiat Oncol. 2014;9:172. doi: 10.1186/1748-717X-9-172.
    1. Leprieur EG, Fernandez D, Chatellier G, et al. Acute radiation pneumonitis after conformational radiotherapy for non-small cell lung cancer: clinical, dosimetric, and associated-treatment risk factors. J Cancer Res Ther. 2013;9(3):447–451. doi: 10.4103/0973-1482.119339.
    1. Baker R, Han G, Sarangkasiri S, et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys. 2013;85:190–195. doi: 10.1016/j.ijrobp.2012.03.041.
    1. Torre-Bouscoulet L, Muñoz-Montaño WR, Martínez-Briseño D, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung cancer. Respir Res. 2018;19:72. doi: 10.1186/s12931-018-0775-2.
    1. Yamaguchi S, Ohguri T, Matsuki Y, et al. Radiotherapy for thoracic tumors: association between subclinical interstitial lung disease and fatal radiation pneumonitis. Int J Clin Oncol. 2015;20(1):45–52. doi: 10.1007/s10147-014-0679-1.
    1. Ueki N, Matsuo Y, Togashi Y, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol. 2015;10:116–125. doi: 10.1097/JTO.0000000000000359.
    1. Lee YH, Kim YS, Lee SN, et al. Interstitial lung change in pre-radiation therapy computed tomography is a risk factor for severe radiation pneumonitis. Cancer Res Treat. 2015;47(4):676–686. doi: 10.4143/crt.2014.180.
    1. Li F, Zhou Z, Wu A, et al. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol. 2018;13:82. doi: 10.1186/s13014-018-1030-1.
    1. Chen H, Senan S, Nossent EJ, et al. Treatment-related toxicity in patients with early-stage non-small cell lung cancer and co-existing interstitial lung disease: a systematic review. Int J Radiat Oncol Biol Phys. 2017;98(3):622–631. doi: 10.1016/j.ijrobp.2017.03.010.
    1. Onishi H, Yamashita H, Shioyama Y, et al. Stereotactic body radiation therapy for patients with pulmonary interstitial change: high incidence of fatal radiation pneumonitis in a retrospective multi-institutional study. Cancers (Basel) 2018;10(8):257. doi: 10.3390/cancers10080257.
    1. Goodman CD, Nijman SF, Senan S, et al. A Primer on Interstitial Lung Disease and Thoracic Radiation. J Thorac Oncol. 2020;15(6):902–913. doi: 10.1016/j.jtho.2020.02.005.
    1. Yamashita H, Kobayashi-Shibata S, Terahara A, et al. Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol. 2010;5:32. doi: 10.1186/1748-717X-5-32.
    1. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012;185:1147–1153. doi: 10.1164/rccm.201108-1420PP.
    1. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–748. doi: 10.1164/rccm.201308-1483ST.
    1. Glick D, Lyen S, Kandel S, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival in patients treated with lung stereotactic body radiation therapy (SBRT) Clin Lung Cancer. 2018;19(2):e219–226. doi: 10.1016/j.cllc.2017.06.021.
    1. Yamaguchi S, Ohguri T, Ide S, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82:260–265. doi: 10.1016/j.lungcan.2013.08.024.
    1. Sanuki N, Ono A, Komatsu E, et al. Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. J Radiat Res. 2012;53(1):110–116. doi: 10.1269/jrr.110142.
    1. Niska JR, Schild SE, Rule WG, Daninels TB, Jett JR. Fatal radiation pneumonitis in patients with subclinical interstitial lung disease. Clin Lung Cancer. 2018;19(4):E417–E420. doi: 10.1016/j.cllc.2018.02.003.
    1. Kim H, Pyo H, Noh JM, et al. Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: Comparison between X-ray and proton therapy. Radiat Oncol. 2019;14:19. doi: 10.1186/s13014-019-1221-4.
    1. Bahig H, Filion E, Vu T, et al. Severe radiation pneumonitis after lung stereotactic ablative radiation therapy in patients with interstitial lung disease. Pract Radiat Oncol. 2016;6(5):367–374. doi: 10.1016/j.prro.2016.01.009.
    1. Washko GR, Lynch DA, Matsuoka S, et al. Identification of early interstitial lung disease in smokers from the COPDGene Study. Acad Radiol. 2010;17(1):48–53. doi: 10.1016/j.acra.2009.07.016.
    1. Okubo M, Itonaga T, Saito T, et al. Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours. Br J Radiol. 2017;90(1073):20160508. doi: 10.1259/bjr.20160508.
    1. Nakajima M, Yamamoto N, Hayashi K, et al. Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis. Radiat Oncol. 2017;12:144. doi: 10.1186/s13014-017-0881-1.
    1. Onishi H, Yamashita H, Shioyama Y, et al. Stereotactic body radiation therapy for patients with pulmonary interstitial change: high incidence of fatal radiation pneumonitis in a retrospective multi-institutional study. Cancers. 2018;10(8):257. doi: 10.3390/cancers10080257.
    1. Ozawa Y, Abe T, Omae M, et al. Impact of preexisting interstitial lung disease on acute, extensive radiation pneumonitis: retrospective analysis of patients with lung cancer. PLoS ONE. 2015;10:e0140437. doi: 10.1371/journal.pone.0140437.
    1. Bepler G, Dilling TJ, Wagner H, et al. Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2011;6(3):553–558. doi: 10.1097/JTO.0b013e31820b8d88.
    1. Naccache JM, Gibiot Q, Monnet I, et al. Lung cancer and interstitial lung disease: a literature review. J Thorac Dis. 2018;10(6):3829–3844. doi: 10.21037/jtd.2018.05.75.
    1. Tsurugai Y, Takeda A, Sanuki N, et al. Stereotactic body radiotherapy for lung cancer patients with idiopathic interstitial pneumonias. Radiother Oncol. 2017;125(2):310–316. doi: 10.1016/j.radonc.2017.08.026.
    1. Sato T, Teramukai S, Kondo H, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014;147(5):1604–1611.e3. doi: 10.1016/j.jtcvs.2013.09.050.
    1. Morgan G, Breit S. Radiation and the lung: a re-evaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys. 1995;31(2):361–369. doi: 10.1016/0360-3016(94)00477-3.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera